XLO
Xilio Development Inc
NASDAQ: XLO · HEALTHCARE · BIOTECHNOLOGY
$7.92
+1.67% today
Updated 2026-04-30
Market cap
$45.80M
P/E ratio
—
P/S ratio
1.05x
EPS (TTM)
$-4.19
Dividend yield
—
52W range
$6 – $17
Volume
0.2M
Xilio Development Inc (XLO) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | $-17.84M | $-36.09M | $-80.75M | $-75.72M | $-68.62M | $-18.38M | $-4.99M |
| Capital expenditures | $715000.00 | $2.19M | $1.10M | $1.87M | $486000.00 | $36000.00 | $518000.00 |
| Depreciation | — | — | — | — | — | — | — |
| Stock-based comp | $112000.00 | $1.30M | $4.96M | $8.42M | $7.38M | $6.43M | $6.94M |
| Free cash flow | $-18.56M | $-38.28M | $-81.85M | $-77.59M | $-69.11M | $-18.41M | $-5.51M |
| Investing cash flow | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — |
| Net change in cash | — | — | $178.82M | $-77.66M | — | — | — |